JP2025521091A5 - - Google Patents
Info
- Publication number
- JP2025521091A5 JP2025521091A5 JP2024566379A JP2024566379A JP2025521091A5 JP 2025521091 A5 JP2025521091 A5 JP 2025521091A5 JP 2024566379 A JP2024566379 A JP 2024566379A JP 2024566379 A JP2024566379 A JP 2024566379A JP 2025521091 A5 JP2025521091 A5 JP 2025521091A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazino
- piperidine
- methyl
- hexahydro
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340185P | 2022-05-10 | 2022-05-10 | |
| US63/340,185 | 2022-05-10 | ||
| PCT/US2023/066755 WO2023220577A1 (en) | 2022-05-10 | 2023-05-09 | 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025521091A JP2025521091A (ja) | 2025-07-08 |
| JP2025521091A5 true JP2025521091A5 (enExample) | 2026-05-18 |
Family
ID=86771366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566379A Pending JP2025521091A (ja) | 2022-05-10 | 2023-05-09 | がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230365576A1 (enExample) |
| EP (1) | EP4522621A1 (enExample) |
| JP (1) | JP2025521091A (enExample) |
| KR (1) | KR20250011136A (enExample) |
| CN (1) | CN119487036A (enExample) |
| AU (1) | AU2023269778A1 (enExample) |
| CA (1) | CA3252552A1 (enExample) |
| IL (1) | IL316891A (enExample) |
| MX (1) | MX2024013843A (enExample) |
| WO (1) | WO2023220577A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549341A (ja) * | 2020-11-06 | 2023-11-24 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| WO2024208300A1 (zh) * | 2023-04-07 | 2024-10-10 | 南京再明医药有限公司 | Brm选择性降解剂化合物 |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025113460A1 (zh) * | 2023-11-28 | 2025-06-05 | 西藏海思科制药有限公司 | 一种哒嗪并三环衍生物及其在医药上的应用 |
| WO2025193454A1 (en) | 2024-03-01 | 2025-09-18 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| WO2026090411A1 (en) | 2024-10-23 | 2026-04-30 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| CN119504710B (zh) * | 2024-11-18 | 2025-10-17 | 昆明医科大学 | 靶向降解PRMT5的PROTACs化合物及其应用 |
| CN121873038A (zh) * | 2026-03-16 | 2026-04-17 | 南开大学 | 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP2023529908A (ja) * | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| JP2023549341A (ja) * | 2020-11-06 | 2023-11-24 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
-
2023
- 2023-05-09 WO PCT/US2023/066755 patent/WO2023220577A1/en not_active Ceased
- 2023-05-09 CN CN202380048631.8A patent/CN119487036A/zh active Pending
- 2023-05-09 IL IL316891A patent/IL316891A/en unknown
- 2023-05-09 CA CA3252552A patent/CA3252552A1/en active Pending
- 2023-05-09 US US18/314,190 patent/US20230365576A1/en active Pending
- 2023-05-09 KR KR1020247040958A patent/KR20250011136A/ko active Pending
- 2023-05-09 JP JP2024566379A patent/JP2025521091A/ja active Pending
- 2023-05-09 AU AU2023269778A patent/AU2023269778A1/en active Pending
- 2023-05-09 EP EP23731058.6A patent/EP4522621A1/en active Pending
-
2024
- 2024-11-08 MX MX2024013843A patent/MX2024013843A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529908A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| US11786524B2 (en) | Pharmaceutical compounds | |
| KR20240050360A (ko) | Shp2 단백질 분해활성을 갖는 화합물 및 이들의 의약 용도 | |
| JP2023501253A5 (enExample) | ||
| CA2844704C (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| FI4161935T3 (fi) | Brm:ään kohdennettuja yhdisteitä ja niihin liittyviä käyttömenetelmiä | |
| JP2019163277A (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| CN115397821A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| US20120157433A1 (en) | Heteroaryl Compounds as Kinase Inhibitors | |
| JP2022125283A5 (enExample) | ||
| JP2019531274A5 (enExample) | ||
| JP2009513575A5 (enExample) | ||
| SI2797918T1 (en) | Bromodomain inhibitors | |
| JP2011520941A5 (enExample) | ||
| JP2021107456A (ja) | インドリノン化合物の使用 | |
| US20120165306A1 (en) | Pyrazinylpyridines useful for the treatment of proliferative diseases | |
| RU2413726C2 (ru) | Замещенные биарильные аналоги пиперазинилпиридина, их применение в терапии, фармацевтическая композиция, фармацевтический препарат, способы уменьшения проводимости кальция и ингибирования связывания капсаициновых рецепторов | |
| RU2016108038A (ru) | Новые фталазиновые производные и способ их получения | |
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| JP2011513419A5 (enExample) | ||
| KR20170013987A (ko) | 2-아실아미노티아졸 유도체 또는 그의 염 | |
| CN102203060B (zh) | 3-(苄基氨基)-吡咯烷衍生物和它们作为nk-3 受体拮抗剂的应用 | |
| ZA200506460B (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| US20250345339A1 (en) | Doses and regimens of her2 inhibitors |